Item 7.01 Regulation FD Disclosure.
On May 5, 2022, the Company announced that that its subsidiary, BayMedica, will
be providing rare cannabinoids for use in Radicle Science, Inc.’s Radicle Energy
rare cannabinoid study to assess the effects of delta-9 (“d-9”) dominant
tetrahydrocannabivarin (“THCV”) on energy, focus/attention, appetite and
weight/BMI.
The information set forth in this Item 7.01, including Exhibits 99.1, is being
furnished and shall not be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise
subject to the liabilities of that section. The information set forth in this
Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference
into any other filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as shall be expressly set forth by specific reference in
such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
The following exhibits shall be deemed to be furnished, and not filed:
Exhibit No. Description
99.1 News release, dated May 5, 2022
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document and included as Exhibit 101)
1
© Edgar Online, source Glimpses
postbrexitcompliance.com 